Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Adverse events (AEs) in clinical trials may be reported in multiple sources. Different methods for reporting adverse events across trials or across sources for a single trial may produce inconsistent information about the adverse events associated with interventions. METHODS: We compared the methods authors use to decide which AEs to include in a particular source (i.e., "selection criteria"), including the number of different types of AEs reported (i.e., rather than the number of events). We compared sources (e.g., journal articles, clinical study reports (CSRs)) of trials for two drug-indications-gabapentin for neuropathic pain and quetiapine for bipolar depression. Electronic searches were completed in 2015. We identified selection criteria and assessed how criteria affected AE reporting. RESULTS: We identified 21 gabapentin and 7 quetiapine trials. We found 6 gabapentin CSRs and 2 quetiapine CSRs, all written by drug manufacturers. All CSRs reported all AEs without applying selection criteria; by comparison, no other source reported all AEs, and 15/68 (22%) gabapentin sources and 19/48 (40%) quetiapine sources reported using selection criteria. Selection criteria greatly affected the number of AEs reported. For example, 67/316 (21%) AEs in one quetiapine trial met the criterion "occurring in ≥2% of participants in any treatment group," while only 5/316 (2%) AEs met the criterion "occurring in ≥10% of quetiapine-treated patients and twice as frequent in the quetiapine group as the placebo group." CONCLUSIONS: Selection criteria for reporting AEs vary across trials and across sources for individual trials. If investigators do not pre-specify selection criteria, they might "cherry-pick" AEs based on results. Even if investigators pre-specify selection criteria, selective reporting will produce biased meta-analyses and clinical practice guidelines. Data about all AEs identified in clinical trials should be publicly available; however, sharing data will not solve all the problems identified in this study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. (2004) · JAMA · doi:10.1001/jama.291.20.2457 · Cited by 1,845
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis, J. P. A., Evans, S. J. W., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., & for the CONSORT Group* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00009 · Cited by 1,593
Kirkham, J. J., Dwan, K. M., Altman, D. G., Gamble, C., Dodd, S., Smyth, R., & Williamson, P. R. (2010) · BMJ · doi:10.1136/bmj.c365 · Cited by 1,133
Dwan, K., Gamble, C., Williamson, P. R., Kirkham, J. J., & the Reporting Bias Group (2013) · PLoS ONE · doi:10.1371/journal.pone.0066844 · Cited by 1,127
The ClinicalTrials.gov Results Database — Update and Key Issues
Zarin, D. A., Tse, T., Williams, R. J., Califf, R. M., & Ide, N. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmsa1012065 · Cited by 838
Chan, A.-W., & Altman, D. G. (2005) · BMJ · doi:10.1136/bmj.38356.424606.8f · Cited by 613
Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research
Chan, A.-W. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041086 · Cited by 444
Neuraminidase inhibitors for preventing and treating influenza in adults and children
Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Hama, R., Thompson, M. J., Spencer, E. A., Onakpoya, I. J., Mahtani, K. R., Nunan, D., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008965.pub4 · Cited by 382
Trial Reporting in ClinicalTrials.gov — The Final Rule
Zarin, D. A., Tse, T., Williams, R. J., & Carr, S. (2016) · New England Journal of Medicine · doi:10.1056/nejmsr1611785 · Cited by 332
Golder, S., Loke, Y. K., Wright, K., & Norman, G. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002127 · Cited by 277
Cited by
Junqueira, D. R., Zorzela, L., Golder, S., Loke, Y., Gagnier, J. J., Julious, S. A., Li, T., Mayo-Wilson, E., Pham, B., Phillips, R., et al. (2023) · BMJ · doi:10.1136/bmj-2022-073725 · Cited by 281
Self-citationJunqueira, D. R., Zorzela, L., Golder, S., Loke, Y., Gagnier, J. J., Julious, S. A., Li, T., Mayo-Wilson, E., Pham, B., Phillips, R., et al. (2023) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2023.04.005 · Cited by 67
Self-citationHarms in Systematic Reviews Paper 1: An introduction to research on harms
Qureshi, R., Mayo-Wilson, E., & Li, T. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.10.023 · Cited by 63
Self-citationImproving the analysis of adverse event data in randomized controlled trials
Cornelius, V. R., & Phillips, R. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.12.023 · Cited by 27
Metadata
- Authors
- Mayo-Wilson, E., Fusco, N., Hong, H., Li, T., Canner, J. K., & Dickersin, K.
- Venue
- Trials
- Published
- 2019-09-05
- Volume
- 20
- Issue
- 1
- Pages
- 553-553
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2972281968
- Cited by
- 35
- References
- 20
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events. https://app.cochat.ai/papers/10.1186/s13063-019-3581-3
- The paper
- Mayo-Wilson, E., Fusco, N., Hong, H., Li, T., Canner, J. K., & Dickersin, K. (2019). Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events. Trials. https://doi.org/10.1186/s13063-019-3581-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.